The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

Yi Shi, David J. Riese II and Jianzhong Shen*

Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States

Chemokines are a family of small, secreted cytokines which regulate a variety of cell functions. The C-X-C motif chemokine ligand 12 (CXCL12) binds to C-X-C chemokine receptor type 4 (CXCR4) and C-X-C chemokine receptor type 7 (CXCR7). The interaction of CXCL12 and its receptors subsequently induces downstream signaling pathways with broad effects on chemotaxis, cell proliferation, migration, and gene expression. Accumulating evidence suggests that the CXCL12/CXCR4/CXCR7 axis plays a pivotal role in tumor development, survival, angiogenesis, metastasis, and tumor microenvironment. In addition, this chemokine axis promotes chemoresistance in cancer therapy via complex crosstalk with other pathways. Multiple small molecules targeting CXCR4/CXCR7 have been developed and used for preclinical and clinical cancer treatment. In this review, we describe the roles of the CXCL12/CXCR4/CXCR7 axis in cancer progression and summarize strategies to develop novel targeted cancer therapies.

Keywords: C-X-C motif chemokine ligand 12, C-X-C chemokine receptor type 4, C-X-C chemokine receptor type 7, cancer progression, tumor microenvironment

INTRODUCTION

Chemokines are small secreted peptides with molecular weights in the range of 8–12 kD (Rollins, 1997). They are best known for their roles in the mediation of immune cell recruitment (Rot and Von Andrian, 2004). Subsequently, they were reported to play essential roles in various pathological conditions, including inflammation, atherosclerosis, hematopoiesis, and cancer (Romagnani et al., 2004; Ma et al., 2013; Griffith et al., 2014; Wang et al., 2018). Based on the arrangement of the two cysteine residues near the amino terminus, chemokines can be classified into four subfamilies (CC, CXC, CX3C, and C) (Nomiyama et al., 2013). Chemokines exert their function by binding to seven-transmembrane-spanning G protein-coupled cell-surface receptors. Named by their endogenous ligand (chemokines), chemokine receptors are grouped into two subfamilies: conventional chemokine receptors (CCKRs) and atypical chemokine receptors (ACKRs) (Bachelerie et al., 2014). Chemokines binding to CCKRs would induce a conformational change in the receptor, leading to intracellular signal transduction (Kufareva et al., 2015). However, ACKRs do not couple to many signal transduction pathways, which are considered as scavengers for chemokines (Bachelerie et al., 2014).

Stromal cell-derived factor-1 (SDF-1), which is also referred to as CXCL12, is a homeostatic CXC chemokine that possesses seven different isoforms. It is secreted in a wide range of different tissues by stromal cells, fibroblasts, and epithelial cells, regulating hematopoietic cell trafficking and secondary...
CXCL12/CXCR4/CXCR7 Axis in Cancer

**C-X-C MOTIF CHEMOKINE LIGAND 12 AXIS SIGNAL TRANSDUCTION**

CXCL12/CXCR4/CXCR7 can stimulate diversified downstream signaling pathways that regulate chemotaxis, gene transcription, cell survival, and proliferation. Figure 1 presents the principal signaling pathways thought to be involved in CXCL12 signal transduction. The precise transduction may differ between cell types as some features might be tissue-dependent.

CXCL12 binding to CXCR4 promotes a three-dimensional conformation change and initiates the exchange from GTP to GDP, leading to the dissociation of Ga subunit from Gß/Gy dimer (Bajetto et al., 2001). The dissociated Gß/Gy dimer is capable of activating phospholipase C (PLC)-ß, which catalyzes the hydrolysis of phosphatidylinositol (4,5)-bisphosphate (PIP2) into two secondary messengers, inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG). Upon binding with IP3, IP3 receptor (IP3R) triggers the release of calcium from intracellular stores into the cytoplasm (Mellado et al., 2001). DAG promotes the activation of protein kinase C (PKC) and mitogen-activated protein kinase (MAPK), which contributes to chemotaxis (Sun et al., 2002). The Gß/Gy dimer is additionally involved in Ras activation of the MAPK/ERK cascade, inducing profound consequences for gene expression and cell cycle progression (Würth et al., 2014). Based on the coupled Ga subunits, diverse GPCR signaling pathways can be classified into four families: Gaαq, Gaαi, Gaαn, and Gaα12 (Goldsmith and Dhanasekaran, 2007). At first, CXCR4 was classified as a Gaα-protein-coupled receptor (Gupta et al., 1998). The activation of Gaα subunits inhibits adenyl cyclase, which catalyzes 5’adenosine triphosphate into cyclic adenosine monophosphate (cAMP), thereby regulating other downstream effectors (Gerits et al., 2008). Either the Gß/Gy dimer or the Gaα subunit can activate phosphoinositide-3 kinase (PI3K), leading to phosphorylation of multiple focal adhesion proteins and contributing to cell migration (Wang et al., 2000). By generating phosphatidylinositol (3,4,5)-trisphosphate, PI3K can trigger the activation of the serine-threonine kinase AKT, thus stimulating the downstream transcription factor nuclear factor-
κB (NF-κB) and mTOR pathways, which play key roles in tumor cell survival and proliferation (Barbero et al., 2003; Ward, 2006). In addition, Gαi is in some contexts necessary for Rac activation (Li et al., 2013). Despite the well-characterized coupling to Gαi, CXCR4 can also transduce signal through other Gα proteins, such as Gαq and Gα12/13. CXCR4 coupled to Gαq can couple to downstream events via PLC-β, which leads to increased IP3 synthesis and PKC signaling (Princen et al., 2003). CXCR4 stimulation of Gα12/13 can also stimulate Bruton’s tyrosine kinase, which inhibits Fas-mediated apoptosis (Jiang et al., 1998). Furthermore, Gα12/13 is required as a direct activator of Rho through the modulation of Rho-guanine nucleotide exchange factors (Rubin, 2009). CXCR4 signaling is modulated by receptor internalization and lysosomal degradation. Following CXCL12 binding, the intracellular C-terminus of CXCR4 is rapidly phosphorylated at serine sites by G-protein coupled receptor kinases (GRKs), resulting in recruitment of β-arrestin and clathrin-mediated endocytosis (Busillo and Benovic, 2007). β-arrestin prevents the CXCR4 from coupling with G proteins and targets them for lysosomal degradation (Luttrell and Gesty-Palmer, 2010).

Initially, CXCR7 was characterized as a scavenger or decoy receptor for CXCL12 due to the absence of typical intracellular responses (such as intracellular calcium mobilization or modulation of adenylyl cyclase activity) after CXCL12 binding (Zabel et al., 2009). Moreover, unlike CXCR4 internalization, CXCR7 internalization occurs even in the absence of ligand binding and does not result in receptor degradation (Klein et al., 2014). Like CXCR4, CXCR7 can activate numerous intracellular signaling pathways, especially the AKT and MAPK pathways, via G-proteins (Odemis et al., 2012) or by β-arrestin (Gravel et al., 2010). CXCR4 and CXCR7 can each form homo- and heterodimers (Luker et al., 2009). The formation of heterodimers enhances CXCL12-dependent intracellular calcium mobilization and ERK1/2 phosphorylation (Sierro et al., 2007), yet blocks CXCR4 coupling to G protein complexes (Levoye et al., 2009). Therefore, CXCR7 signal transduction is still under intense study, particularly with respect to mechanisms of signaling specificity.

C-X-C MOTIF CHEMOKINE LIGAND 12 AXIS IN TUMOR PROGRESSION

Chemokines and their receptors have long been associated with cancer progression (Vicari and Caux, 2002; Tanaka et al., 2005; Janssens et al., 2018). More recently, the chemokine CXCL12 and its cognate receptors (CXCR4 and CXCR7) have been shown to play central roles in cancer proliferation, angiogenesis, invasion, tumor microenvironment, as well as drug resistance induced by chemotherapy. There appear to be two mechanisms by which CXCL12 affects tumor cell biology: 1) direct stimulation of signaling pathways that promote cancer cell growth, metastasis, and angiogenesis; 2) indirect effects, including the recruitment of CXCR4/CXCR7-positive cancer cells to CXCL12-expressing organs (Duda et al., 2011).
One of the major biological effects modulated by the CXCL12 axis is to promote tumor cell survival and proliferation. In 1998, Sehgal et al. first found CXCR4 was overexpressed in glioblastoma cell lines, and the expression of antisense CXCR4 inhibited glioma cell proliferation (Sehgal et al., 1998). Furthermore, exogenous CXCL12 induces proliferation in a dose-dependent manner in human glioblastoma cell lines (Barbero et al., 2003). The CXCL12 axis has been identified to induce proliferation of cell lines derived from many types of cancers, including prostate cancer (Fernandis et al., 2002), breast cancer (Ueda et al., 2006), lung cancer (Miao et al., 2007), multiple myeloma (Beider et al., 2011), and pancreatic cancer (Gao et al., 2010). The CXCL12/CXCR4 interaction phosphorylates CXCR4, subsequently promotes calcium flux, and directly activates MAPK, PI3K, Wnt, and Sonic Hedgehog signaling pathways, thus inducing proliferation of various types of tumor cells (Getts et al., 2014). The activated MAPK alters translation of mRNA and phosphorylates several other cellular proteins (c-Myc and RSK kinases) that are critical to cell proliferation, cell cycle progression, cell division, and differentiation. CXCR4 expression can be upregulated by the transcription factor c-Myc, which in turn activates MAPK. Therefore, CXCR4 expression and MAPK signaling form a positive feedback loop to further sustain proliferative signaling (Figure 2) (Thomas et al., 2008).

Activation of CXCR4 also increases expression of EGF/EGFR signaling proteins, leading to increased cell proliferation (Weekes et al., 2012). Wnt signaling plays a pivotal role in CXCL12-induced tumor cell proliferation, as silencing CXCL12/CXCR4 signaling influences pancreatic cancer cell phenotypes and inhibits tumor cell proliferation in vitro via inactivation of the canonical Wnt pathway (Wang et al., 2008b). Additionally, the activation of AKT and ERK signaling pathways by the CXCL12 axis promotes nuclear accumulation of NFκB and increases NFκB signaling by inducing the phosphorylation and destabilization of IκB-α, followed by SHH up-regulation (Singh et al., 2012). Moreover, SHH signaling exerts its paracrine effect mainly by activating protein patched homolog (Ptch) on the surrounding stromal cells and subsequently induces additional CXCL12 expression and extracellular release to complete a positive pro-proliferative feedback loop (Figure 2) (Sleightholm et al., 2017). CXCR7 activates the AKT signaling pathway and stimulates EGFR signaling, thereby increasing tumor cell proliferation and survival (Wang et al., 2008a; Singh and Lokeshwar, 2011). Moreover, CXCR7 overexpression and gene silencing in tumor cells collectively support the role of CXCR7 contribution to tumor growth (Miao et al., 2007; Meijer et al., 2008). However, study in neuroblastoma (NB) indicated that CXCR7 activation strongly reduced the NB cell growth through ERK1/2 cascade both in vitro and in vivo (Liberman et al., 2012). Likewise, CXCR7 has been found associated with suppressing tumor growth and migration in colon cancer (Heckmann et al., 2014). These findings reflect a controversial role of CXCR7 in tumor cell proliferation, which also indicates that the function of CXCR7 might be cell type-specific. Extensive studies of its role in different malignancies would be beneficial for achieving precision medicine.

The CXCL12 axis also indirectly exerts anti-apoptotic effects in tumor cells. As mentioned previously, the CXCL12/CXCR4 axis activates AKT and ERK, subsequently leading to NFκB accumulation, which can suppress apoptotic signaling (Ganju et al., 1998). The induction of MAPK-ERK and PI3K pathways by CXCL12 inactivates the pro-apoptotic BAD (Bcl2-associated
agonist of cell death) protein (Suzuki et al., 2001). This may arise through ERK phosphorylation of Bad on serine 112, which results in the dissociation of Bad from Bcl-2 and enables Bcl-2 to exert its anti-apoptotic effects (Scheid et al., 1999). Similarly, the CXCL12/CXCR4 axis may stimulate ERK phosphorylation of Bim, resulting in Bim dissociation from the anti-apoptotic proteins Bcl-2 and Mcl-1 and enabling the free Bcl-2 and Mcl-1 to exert their anti-apoptotic effects by binding to Bax (McCubrey et al., 2007). CXCR7 signaling also suppresses apoptosis. CXCR7 overexpression reduces the apoptotic fraction in prostate cancer cells and protects these cells from apoptosis (Wang et al., 2008a). Likewise, knockdown of CXCR7 in the MCF7 breast cancer cell line increased the expression of the pro-apoptotic caspase three and eight proteins (Gao et al., 2015).

Another function of the CXCL12 axis in tumor cell growth and survival is evading growth suppression, which is most commonly regulated through the Rb or p53 pathways. Wildtype p53 binds to the GFI-1 binding site in the proximal enhancer region of the CXCR4 gene, which suppresses CXCR4 expression (Katoh and Katoh, 2010). Treatment with p53 rescue drugs (PRIMA-1, CP-31398) in p53 mutant cells can restore the suppression of CXCR4 transcription in cells with mutant p53. Loss of functional p53 is commonly observed in many cancer cell lines, which is one of the mechanisms resulting in CXCR4 upregulation. As mentioned before, the CXCL12/CXCR4 axis increases the expression of prosurvival proteins MDM-2 and NFkB through AKT activation. Specifically, MDM-2 phosphorylation of p53 directly leads to its degradation through ubiquitin-dependent proteolysis, thereby promoting tumor cell survival and proliferation (Sleightholm et al., 2017).

C-X-C Motif Chemokine Ligand 12 Axis in Angiogenesis

Both in vitro and in vivo studies suggest that the expression level of CXCL12/CXCR4 in cancer cells is positively correlated with microvesSEL density. Initially, the angiogenic activity of CXCR4 was inferred in mice lacking CXCL12 or CXCR4 (Tachibana et al., 1998). For example, mice lacking CXCR4 or CXCL12 are defective in the formation of the large vessels supplying the gastrointestinal tract and exhibit defects in vascular development, hematopoiesis, and cardiogenesis. Moreover, CXCR4 is highly expressed in the endothelial cells of large vessels in tumor stroma, indicating that the CXCL12/CXCR4 signaling plays a vital role in tumor angiogenesis (Hayashi and Kume, 2008). There are four possible mechanisms by which CXCL12/CXCR4 regulates tumor angiogenesis: 1) upregulates vascular endothelial growth factor (VEGF) expression in tumor tissue through the PI3K/Akt signaling pathway; 2) reduces the expression of glycolytic enzyme phosphoglycerate kinase 1 (PGK1) which suppresses the secretion of VEGF; 3) upregulates several angiogenesis-associated genes in cancer cells; and 4) directs the recruitment of endothelial progenitor cells to the vicinity of neovascularization.

Among various factors involved in tumor angiogenesis, VEGF and its receptor VEGFR play a major role (Carmeliet, 2005). VEGF can regulate angiogenesis indirectly by inducing endothelial cells to express MMP-2 and MMP-9, thereby enabling chemotaxis of endothelial cells and the formation of capillary channels, and thus indirectly regulate angiogenesis (Lafleur et al., 2003). Moreover, CXCR4/CXCL12 induces AKT phosphorylation, which can upregulate VEGF transcription and protein expression (Liang et al., 2007). Under hypoxic conditions, hypoxia-inducible factor 1 (HIF-1) and VEGF increase the expression of CXCR4 in human brain microvascular endothelial cells, which promotes glioblastoma angiogenesis (Zagzag et al., 2006). CXCL12 can induce MMP-2 and MMP-9 upregulation in pancreatic cancer cells (Pan et al., 2013). Phosphoglycerate kinase 1 (PGK1) is an ATP-generating glycolytic enzyme that catalyzes the reversible transfer of a phosphate group from 3-biphosphoglycerate (3-BPG) to ADP, producing 3-phosphoglycerate (3-PG) and ATP. PGK1 is secreted extracellularly by different types of tumors, acting as a disulfide reductase that serves to cleave plasminogen, thereby generating the tumor blood vessel inhibitor angiostatin (Chen et al., 2003; Daly et al., 2004; Hwang et al., 2006). Hyper levels of CXCL12 signaling through CXCR4 reduces PGK1 expression and promote angiogenesis (Wang et al., 2007). Another mechanism by which CXCL12 contributes to tumor angiogenesis is through the upregulation of angiogenesis-associated genes, among which IL-6 is the earliest and highest upregulated gene. For example, CXCL12 induces time- and dose-dependent upregulation of IL-6 transcription and protein secretion. This transcriptional regulation of IL-6 by CXCL12 is mediated by phosphorylation of ERK and activation of the NFkB complex (Chu et al., 2009). IL-6 induces other angiogenic factors, such as VEGF, basic fibroblast growth factor (bFGF), and COX-2 (Jee et al., 2004). Endothelial progenitor cells (EPCs) are pluripotent stem cells with the potential to differentiate into mature endothelial cells. Thus, EPCs play a pivotal role in tumor angiogenesis. In a coimplantation xenograft model, carcinoma-associated fibroblasts (CAFs) extracted from human breast carcinomas promoted the growth of admixed breast carcinoma cells by recruiting EPCs into the tumors (Orimo et al., 2005). Furthermore, CAFs secrete CXCL12 and the recruitment of EPCs is regulated in part by CXCL12. Moreover, CXCL4 is expressed on EPCs, thereby mediating CXCL12 signaling (Qin et al., 2016). Finally, the CXCL12/CXCR4 axis increases progesterone-induced EPC viability through the PI3K/AKT pathway (Yu et al., 2016). Plasmacytoid dendritic cells (DCs), which induce neoangiogenesis through production of IL-8 and TNF-α, could be attracted to the tumor environment by CXCL12 (Curiel et al., 2004). Extensive CXCR7 has been observed in diverse tumor-associated blood vessels (Sánchez-Martín et al., 2011) and could be upregulated in endothelial cells by hypoxia (Bosco et al., 2006). The immunohistochemical staining results demonstrated that CXCR7 was widely expressed in human breast and lung cancers, where it was highly expressed on a majority of tumor-associated blood vessels and malignant cells but not expressed on normal vasculature (Miao et al., 2007). Downregulation of CXCR7 expression by siRNA resulted in the formation of smaller tumors by these cells. These results are consistent in clinical biopsy samples of ovarian cancer, bladder cancer, kidney cancer, and malignant gliomas.
C-X-C Motif Chemokine Ligand 12 Axis in Invasion and Metastasis

Metastasis is an important biological characteristic of malignant tumors, which is the key cause of death among cancer patients. Tumor metastasis was once recognized as a passive consequence of a single tumor cell escaping from a primary tumor. However, recent data indicated that tumor metastasis is an active process employing multiple molecular and cellular mechanisms (Chambers et al., 2002). The CXCL12 axis is also involved in metastasis of many human cancers, such as pancreatic cancer (Wang et al., 2008b), melanoma (Bartolomé et al., 2009), and colon cancer (Zeeenberg et al., 2003).

In 2001, Muller et al. provided the first evidence that the CXCL12/CXCR4 axis mediates human breast cancer metastasis (Müller et al., 2001). For example, a CXCR4 neutralizing antibody CXCL12/CXCR4 axis mediates human breast cancer metastasis and shRNA knockdown of the CXCR4 receptor significantly reduced tumor cell invasion (Krohn et al., 2009). Moreover, CXCL12 is highly expressed in liver and specifically attracts melanoma and CXCR4 (+) cells, thereby increasing cancer liver metastasis (Kim et al., 2006). Upon further study, the CXCL12/CXCR4 axis was shown to regulate metastasis via different mechanisms. Epithelial-to-mesenchymal transition (EMT) has been recognized as an important process that is associated with cancer metastasis. CXCL12/CXCR4 signaling stimulated the SHH signaling pathway, which is associated with EMT and loss of cell adhesion (Li et al., 2012). Moreover, CXCL12/CXCR4 signaling upregulates survivin via the MED/ERK and PI3K/AKT pathways, giving rise to cell cycle CXCL12/CXCR4 signaling upregulates survivin via the MED/ERK and PI3K/AKT pathways, giving rise to cell cycle disruption (Liao et al., 2016) and hepatocellular carcinoma (Li et al., 2014). Moreover, CXCL12/CXCR4 signaling stimulates invasion and EMT of colorectal cancer cells through the Wnt/β-catenin signaling pathway (Huh et al., 2014). Metalloprotease (MMPs) are a family of enzymes involved in the degradation of extracellular matrix in the surrounding normal tissue with the ability to mediate cancer invasion and metastasis (Egeblad and Werb, 2002). CXCL12 promotes invasion of bone by myeloma cells by stimulating MMP-9 and MT1-MMP expression (Parmo-Cabañas et al., 2006). Similarly, CXCR4 promotes the migration and invasion by tongue squamous cell carcinoma cells by stimulating MMP-9 and MMP-13 expression by the ERK pathway (Yu et al., 2011). CXCL12/CXCR4 axis can stimulate the MMP-2 secretion of other types of cells; for example, CXCL12/CXCR4 signaling stimulates the migration of neuroblasts along the corpus callosum (Mao et al., 2016). Tumors are often hypoxic, resulting in upregulation of CXCL12 expression in endothelial cells by HIF-1. Therefore, CXCR4-positive cancer stem cells are likely to be attracted to the peripheral vessels, thereby serving as a pool for metastasis (Ratajczak et al., 2006). CXCL12 also modulates the expression and function of cell surface integrins, thereby promoting tumor cell adhesion. For example, CXCL12 increases the adhesion of PC-3 cells to the human umbilical vein endothelial cell monolayer in a model of tumor extravasation or intravasation (Kukreja et al., 2005). Moreover, CXCL12 stimulates the expression of α5 and β3 integrins by prostate tumor cells (Engl et al., 2006), thereby inducing the adhesion of the tumor cells to human endothelium or extracellular matrix. Similarly, CXCL12 induces integrin β1 expression by ovarian tumor cells, leading to increased adhesion of these cells to laminin (Shen et al., 2009).

It has been postulated that CXCR7 expression is associated with increased tumor cell adhesion, which provides these tumor cells with a growth and survival advantage (Burns et al., 2006). Indeed, overexpression of CXCR7 enhances breast cancer cell adhesion to human umbilical vein endothelial cells (HUVECs). Likewise, increased CXCR7 expression is associated with increased prostate cancer cell aggressiveness; this effect appears to be mediated by cell adhesion proteins CD44 and cadherin-11 (Wang et al., 2008b). Collectively, these data suggest that CXCR7 functions as an oncogene, although much remains to be elucidated, particularly with respect to mechanisms of CXCR7 oncogenic signaling. CXCR7 deficient mice exhibit greater local recurrence of breast cancer following resection, suggesting that CXCR7 may possess breast cancer tumor suppressor activities related to the metastatic cascade (Stacer et al., 2016). This apparent conundrum may reflect the fact that CXCR7 can heterodimerize with CXCR4 and that loss of CXCR7 may disrupt the balance between oncogenic CXCR4/CXCR7 heterodimers and tumor suppressor homodimers. Clearly, this apparent dichotomy regarding CXCR7 function is yet to be definitively resolved.

C-X-C Motif Chemokine Ligand 12 Axis in Tumor Microenvironment

The importance of the microenvironment to tumor progression is well established (Horgan et al., 1987; Barcellos-Hoff and Ravani, 2000; Bhowmick et al., 2004). The tumor microenvironment (TME) consists of resident non-cancerous cells (stromal fibroblasts, endothelial cells, and immune cells), proteolytic enzymes, growth factors, inflammatory cytokines, and the extracellular matrix (ECM) (Spill et al., 2016). CXCL12 regulates tumor-TME interactions, thereby promoting tumor survival, proliferation, angiogenesis, and metastasis (Burger and Kipps, 2006).

CXCL12 secreted by carcinoma-associated fibroblasts (CAFs) stimulates tumor growth directly, acting through CXCR4 expressed by breast cancer cells and promoting invasiveness (Orimo et al., 2005). CXCL12 also functions as a chemoattractant during tumor development. For example, CXCR4-positive cancer cells can be recruited to organs with high expression of CXCL12, including liver, lungs, and bone marrow (Wang et al., 2008b; Konopleva and Jordan, 2011). CXCR4 activation induces leukemia cell trafficking and...
homing to the bone marrow microenvironment because of the constitutive secretion of CXCL12 by stromal cells in bone marrow (Burger and Peled, 2009). At the same time, CXCL12 can attract CXCR4-positive inflammatory, vascular, and stromal cells into the tumor mass to support tumor development. This is a major contribution, as CXCR4 is expressed by many cell types in TME, including endothelial cells, epithelial cells, and lymphocytes (Burger and Kipps, 2006). It has been suggested that CAFs promote angiogenesis by recruiting endothelial progenitor cells (EPCs) into carcinomas, which is mediated by CXCL12 (Orimo et al., 2005). In vivo studies demonstrated that activation of CXCL12/CXCR4 accelerates the recruitment of fibroblasts and facilitates cancer stromal formation (Katoh et al., 2010). In a recent study, CXCL12 produced by both the multiple myeloma (MM) cells and bone marrow stromal cells (BMSCs) was found to regulate monocyte migration (Beider et al., 2014). And the blockage with anti-CXCR4 antibodies caused significant inhibition of monocyte recruitment. Monocytes differentiate into macrophages that support tumor cell proliferation, angiogenesis, and shape the immunosuppressive microenvironment. Besides, CXCL12 can trigger anti-apoptotic and proliferative signals in colon cancer cells by inducing mononuclear phagocytes to release HB-EGF, which binds the Epidermal Growth Factor Receptor (EGFR/HER1) and stimulates its signaling (Rigo et al., 2010). In addition, the stroma cells from specialized microenvironments are capable of modulating CXCR4 expression. For example, CFA secretion of transforming growth factor-β (TGF-β) potentiates CXCR4 stimulation of AKT signaling in human prostate epithelial cells, which indicates that synergism between TGF-β, CXCL12, and CXCR4 in tumor stroma contributes to carcinogenesis (Ao et al., 2007).

A recent study reported that CXCR7 is highly expressed on a majority of tumor-associated blood vessels (Miao et al., 2007). Moreover, CXCR7 expression is upregulated in human microvascular endothelial cells under hypoxic and acidic pH conditions, which are well-known characteristics of the TME (Monnier et al., 2012). Another work indicates that CXCR7 is also involved in TGF-β induced EMT in lung adenocarcinoma (Wu et al., 2016). Furthermore, regulation of the macrophage colony-stimulating factor/macrophage colony-stimulating factor receptor signaling pathway enables CXCR7 to recruit tumor-promoting macrophages to the tumor site (Wani et al., 2014). Finally, bone marrow microenvironment is necessary for CXCR7 activation, thereby promoting osteosarcoma invasion (Han et al., 2017). Altogether, these results strongly indicate that CXCR7 modulates cancer survival and metastasis via novel pathways involved in the tumor microenvironment.

### Transcriptional Regulation of C-X-C Motif Chemokine Ligand 12 Axis
In addition to the biological effects mediated by CXCL12 axis, investigations are also conducted associated with the transcriptional regulation of CXCL12 axis during cancer progression. Chen et al. reported that c-Myb could elevate CXCL12 expression by activating CXCL12 promoter in breast cancer cells (Chen et al., 2010). In pancreatic stellate cells, Galectin-1 was observed to induce CXCL12 secretion by activating NF-κB signaling pathway, thereby increasing pancreatic cancer metastasis (Qian et al., 2017). Recent work indicated that c-Myc regulates pancreatic cancer progression via HIF-1α/CXCL12/CXCR4 signaling pathway (Liu et al., 2020). Knocking down of c-Myc significantly decreased CXCL12 expression and inhibited the invasion of pancreatic cancer cells. Moreover, the activating transcription factor 3 (ATF3) and the c-Jun dimerization protein2 (JDP2) inhibit CXCL12 secretion in tumor-associated fibroblasts in a lung carcinoma murine model (Avraham et al., 2019). NF-κB is one of the major transcription factors that regulate CXCR4 expression (Zhi et al., 2015). Further study revealed that elevated levels of NF-κB O-GlcNAcylation promoted CXCR4 expression in cervical cancer cells, thereby increasing lung metastasis (Ali et al., 2017). Furthermore, other transcription factors have also been suggested to increase mRNA and protein of CXCR4 in cancer development, including Runt-related transcription factor 2 (RUNX2) (Guo et al., 2016) and POU1F1transcription factor (Put-I) (Martinez-Ordoñez et al., 2018). Similarly, overexpression of RUNX2 can induce CXCR7 transcription in prostate cancer (Bai et al., 2019). Another study demonstrated that CXCR7 expression had been upregulated by interleukin 6 (IL6) that is mainly derived from cancer-associated fibroblasts, contributing to chemoresistance in esophageal squamous cell carcinoma (Qiao et al., 2018).

### C-X-C MOTIF CHEMOKINE LIGAND 12 AXIS PROMOTES CHEMORESISTANCE
The CXCL12 axis can contribute to tumor chemoresistance. For example, cancer chemotherapy upregulates CXCL12 and CXCR4 expression in multiple cancers (Shaked et al., 2008; Kioi et al., 2010). Moreover, patients who developed distant recurrence of rectal cancers exhibited much higher expression of both CXCR4 and CXCL12 than did patients who did not develop distant recurrence (Saigusa et al., 2010). A more direct evaluation of the role that the CXCL12 axis plays in chemoresistance indicates that the upregulation of CXCR4 in non-small cell lung carcinoma (NSCLC) mediates Gefitinib-resistance associated with EMT (Hu et al., 2017). Furthermore, the cancer progenitor population can be maintained by CXCR4 in tamoxifen-resistant breast cancer MCF7 cells by inducing AhR signaling (Dubrovskia et al., 2012). CXCL12 enhances the resistance of chronic myeloid leukemia to adriamycin (ADM) by stimulating the expression of CXCR4. The mechanism features activation of the downstream PI3K/AKT pathway, translocation of NF-κB dimers into the nucleus, and subsequent decrease of the expression of apoptosis-related proteins (Wang et al., 2014). Similarly, resistance to ADM can be partially reversed by CXCR4 silencing, and lapatinib-resistant cells exhibit greater CXCR4 expression than parental (sensitive) cells (De Luca et al., 2014). This chemoresistance is thought to be mediated by Src and CXCR4 signaling, particularly because CXCR4 antibody treatment reduces the invasive ability of cancer cells. Synthetic Exosome-Like Nanoparticles (SELNs)
has been demonstrated to evoke apoptosis of human pancreatic cancer. However, further investigation indicated that SELNs induce the activation of NF-κB, the expression and secretion of CXCL12, and stimulation of CXCR4/AKT survival pathway, resulting in protection of these tumor cells from death (Beloribi-Djefallah et al., 2015). As mentioned before, CAF-secreted IL-6 stimulates the upregulation of CXCR7 through STAT3/NF-κB signaling, promoting resistance of esophageal squamous cell carcinoma cells against cisplatin and 5-FU (Qiao et al., 2018). Taken together, these findings illustrate the contribution of CXCL12 axis to cancer chemoresistance.

THERAPEUTIC TARGETING C-X-C MOTIF CHEMOKINE LIGAND 12 AXIS

The CXCL12/CXCR4/CXCR7 axis is a potential target for cancer therapies. Up to now, several molecules have been developed to target CXCL12, CXCR4, or CXCR7. A deep understanding of CXCL12 axis in therapeutic applications would be beneficial for future translation of CXCL12, CXCR4, and CXCR7 inhibitors into clinical use.

Prognostic Marker

Crowther-Swanepoel et al. first reported that functional coding mutations in CXCR4 might contribute to familial chronic lymphocytic leukemia (Crowther-Swanepoel et al., 2009). Similarly, genotyping 466 acute myeloid leukemia patients and 460 healthy controls indicates that a polymorphism in rs2228014 in the CXCR4 coding sequence is significantly increased in AML patients relative to healthy controls (Zheng et al., 2016). Moreover, CXCL12 and CXCR4 polymorphisms appear to contribute to increased risk of hepatocellular carcinoma (HCC) and may be potential markers for HCC (Chang et al., 2009; Qin et al., 2018). CXCR4 expression in triple-negative breast cancer (TNBC) cells correlates positively with histopathological grade but negatively with lymph node metastasis (Guembarovski et al., 2018). Moreover, heterozygosity for either CXCL12 and CXCR4 variants increases the risk for TNBC by analyzing genetic polymorphisms in 59 TNBC patients and 150 healthy control women. Similarly, it appears that a CXCR4 rs2228014 polymorphism is significantly associated with poor progression-free survival (PFS) in metastatic colorectal cancer patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the patients (Matsusaka et al., 2017). Although CXCR4 expression is a prognostic factor in several human tumor types, none of the

Clinical Application

Plerixafor (AMD3100) is a CXCR4 antagonist that was formally approved by the US FDA in 2008 to use in combination with autologous transplantation in patients with Non-Hodgkin’s Lymphoma or multiple myeloma (De Clercq, 2019). By blocking the interaction between CXCL12 and CXCR4, plerixafor triggers the mobilization of stem and progenitor cells (CD34+ cells) (DiPersio et al., 2009). These stem cells are then collected and used in autologous stem cell transplantation to rescue the hematopoietic toxicity and to reconstitute hematopoiesis following high-dose chemotherapy. Furthermore, plerixafor injection is used in combination with a granulocyte-colony stimulating factor (G-CSF) medication to prepare the blood for an autologous stem cell transplant. A clinical study involved patients with non-Hodgkin’s lymphoma or multiple myeloma showed the combination of plerixafor and G-CSF was superior to G-CSF alone in mobilizing hematopoietic progenitor cells (Flomenberg et al., 2005). Recent clinical trials indicate that plerixafor could be used in other strategies for treating cancer. A phase 1/2 study indicated that the addition of plerixafor to cytotoxic chemotherapy could increase the rates of remission in acute myeloid leukemia (Uy et al., 2012). Similarly, the combination of radiochemotherapy (RTCT) and plerixafor yielded a greater delay in tumor growth and lymph node metastasis in patients with cervical cancer than did RTCT alone (Chaudary et al., 2017). Moreover, the combination of plerixafor and bortezomib yielded a strong response rate in
relapsed/refractory multiple myeloma (Ghobrial et al., 2019). According to the clinical studies, combination with other current cancer therapies would be the primary application ofplerixafor or other CXCR4 antagonists. Therefore, pharmacokinetic studies and rational design of dosage are definitely required to avoid potential side effects.

Cancer Immunotherapy

According to the major role of CXCL12 axis in TME, lots of antagonists targeting CXCL12axis were proposed as monotherapy to promote antitumor immunity or in combination with other immunotherapies for cancer treatment. In a mouse model of ovarian cancer, AMD3100 treatment showed significant increases in T-cell–mediated antitumor immune responses, resulting in CXCR4 positive tumor apoptosis and necrosis (Righi et al., 2011). Similar results were obtained in multiple cancer models, that AMD3100 administration leads to rapid T cell accumulation and acted synergistically with immunological checkpoint antagonists (anti-PD-L1) (Feig et al., 2013; Chen et al., 2015). AMD3100 also increases the efficiency of the mesothelin-targeted immune-activating fusion protein (VIC-008) in mesothelioma, which is regulated by PD-1 suppression in CD8+T cells and conversion of regulatory T into helper-like cells (Li et al., 2018). Another study focused on chemoresistant ovarian cancer reported a novel oncolytic vaccinia virus expressing a CXCR4 antagonist that can reduce the immunosuppressive network and increase tumor apoptosis and phagocytosis alone or in combination with doxorubicin (Komorowski et al., 2016). Genget al. developed a new FAPα-targeted vaccine for the treatment of breast cancer (Geng et al., 2019). This DNA vaccine enhanced antigen secretion and effectively decreased the number of CAFs in the TME, leading to decreases in CCL2 and CXCL12 expression, thereby reducing the myeloid-derived suppressor cells in the TME. In glioblastoma, CXCR7-targeted antibody (X7Ab) enhanced tumor cell phagocytosis by increasing macrophages activity (Salazar et al., 2018). And combining X7Ab with Temozolomide (TMZ) significantly slowed mouse glioma progression with prolonged survival.

Cancer immunotherapy targeting CXCL12 axis are giving encouraging results. Further clinical studies based on these findings should be performed to increase the effectiveness of cancer therapy.

CONCLUSION

Compelling evidence has demonstrated that CXCL12/CXCR4/ CXCR7 axis is implicated in tumor growth, survival, angiogenesis, metastasis, tumor microenvironment, and chemoresistance. Thus, the CXCL12 axis is a promising target for therapeutic intervention. However, only a few drugs that target the CXCL12 axis have been approved for clinical use. CXCL12 and its receptors play important roles in homeostasis and non-pathologic inflammation, which might predict that agents that target the CXCL12 axis would possess significant on-target toxicities. Furthermore, crosstalk between CXCR4 and CXCR7 makes specific CXCR4 targeting more challenging. Relatively little is known about the function of CXCR7 and its signal transduction in cancer genesis and/or progression. Elucidating these functions and their mechanisms will undoubtedly contribute to the development of better anticancer agents that target the CXCL12 axis. In clinical applications, the development of targeted drug delivery systems for CXCR4 antagonists should be considered to increase the efficacy of these therapies and to reduce their side effects.

AUTHOR CONTRIBUTIONS

YS collected the original materials and wrote the first draft. DJR and JS made significant changes on the scope and format of this review.

FUNDING

This study was supported partially by NIH funding 1R01HL125279-01A1 (JS).
Gao, Z., Wang, X., Wu, K., Zhao, Y., and Hu, G. (2010). Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis. Pancreatology 10, 186–193. doi:10.1159/000283512
Geng, F., Guo, J., Guo, Q. Q., Xie, Y., Dong, L., Zhou, Y., et al. (2019). A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer. Vaccine 37, 4382–4391. doi:10.1016/j.vaccine.2019.06.012
Gerits, N., Kostenko, S., Shiryaev, A., Johansson, M., and Moens, U. (2008). Relations between the mitogen-activated protein kinase and the CAMP-dependent protein kinase pathways: comradeship and hostility. Cell. Signal. 20, 1592–1607. doi:10.1016/j.cellsig.2008.02.022
Ghobrial, I. M., Liu, C. J., Zavidji, O., Azab, A. K., Bar, R., Laubach, J. P., et al. (2019). Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am. J. Hematol. 94, 1244–1253. doi:10.1002/ajh.25627
Gouni-Berthold, V., and Dhanasekaran, M. (2007). G protein regulation of MAPK networks. Oncogene 26, 3122–3142. doi:10.1038/sj.onc.1210407
Gravel, S., Malouf, C., Boulais, P. E., Berchiche, Y. A., Oishi, S., Fujii, N., et al. (2010). The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J. Biol. Chem. 285, 37939–37943. doi:10.1074/jbc.C110.147470
Griffith, J. W., Sokol, C. L., and Luster, A. D. (2014). Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32, 659–702. doi:10.1146/annurev-immunol-032713-120145
Guembarovski, A. L., Guembarovski, R. L., Hirata, B. K. B., Vitiello, G. A. F., Goldsmith, Z., and Dhanasekaran, D. (2007). G protein regulation of MAPK activity by altering the tumor microenvironment in a murine model of breast cancer. Biochem. Biophys. Res. Commun. 379, 1483. doi:10.1016/j.bbrc.2007.12.183
Guo, Z., Jiang, Y., Hu, X., Wu, W., Zhao, Y., and Hu, G. (2014). Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res. 16, R28. doi:10.1186/bcr3607
Hirata, H., Hinoda, Y., Kikuno, N., Kawamoto, K., Dahiya, A. V., Suehiro, Y., et al. (2007). CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin. Canc. Res. 13, 5056–5062. doi:10.1158/1078-0432.CCR-07-0859
Horgan, K., Jones, D., and Mansel, R. (1987). Mitogenicity of human fibroblasts in vivo for human breast cancer cells. Br. J. Surg. 74, 227–229. doi:10.1002/bjs.1800740326
Hu, T. H., Yao, Y., Yu, S., Han, L. L., Wang, W. J., Guo, H., et al. (2014). SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/β-catenin signaling pathway. Canc. Lett. 345, 417–426. doi:10.1016/j.canlet.2014.08.012
Hu, Y., Zhang, J., Qin, X., Yan, D., Cao, H., Zhou, L., et al. (2017). Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW9365 reverses gefitinib resistance through inhibition of vimentin. OncoTargets Ther. 10, 2341. doi:10.2147/OTT.S124757
Hwang, T. L., Liang, Y., Chien, K. Y., and Yu, J. S. (2006). Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Protoplasma 239, 2259–2272. doi:10.1002/prot.20505
Ieranò, C., Santagata, S., Napolitano, M., Guardia, F., Grimaldi, A., Antignani, E., et al. (2014). CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis. 5, e1310. doi:10.1038/cddis.2014.269
Imai, H., Sunaga, N., Shimizu, Y., Kakegawa, S., Shimizu, K., Sano, T., et al. (2010). Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. Int. J. Immunopathol. Pharmacol. 23, 153–164. doi:10.1177/039439031002300114
Ishigami, S., Natsugo, S., Okumura, H., Matsumoto, M., Nakajo, A., Uenosono, Y., et al. (2007). Clinical implication of CXCL12 expression in gastric cancer. Ann. Surg Oncol. 14, 3154–3158. doi:10.1245/s10434-007-9521-6
Janssens, R., Struyf, S., and Proost, P. (2018). Pathological roles of the homeostatic chemokine CXCL12. Cytokine Growth Factor Rev. 44, 51–68. doi:10.1016/j.cytogfr.2018.10.004
Jee, S. H., Chu, C. Y., Chiu, H. C., Huang, Y. L., Tsai, W. L., Liao, Y. H., et al. (2004). Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. Int. J. Cancer. 113, 56–61. doi:10.1002/ijc.16281
Jiang, Y., Ma, W., Wan, Y., Kozasa, T., Hattori, S., and Huang, X. Y. (1998). The G protein Gα12 stimulates Bruton’s tyrosine kinase and a rasGAP through a conserved PH/BM domain. Nature 395, 808. doi:10.1038/27454
Jiang, Y. P., Wu, X. H., Shi, B., Wu, W. X., and Yin, G. R. (2006). Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol. Oncol. 103, 226–233. doi:10.1016/j.ygyno.2006.02.036
Kang, H., Watkins, G., Parr, C., Douglas-Jones, A., Mansel, R. E., and Jiang, W. G. (2005). Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res. 7, R402. doi:10.1186/bcr1022
Katoh, H., Hosono, K., Ito, Y., Suzuki, T., Ogawa, Y., Kubo, H., et al. (2010). COX-2 and prostaglandin EP2/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am. J. Pathol. 176, 1469–1483. doi:10.2353/ajpath.2010.090607
Katoh, M., and Katoh, M. (2010). Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGBeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int. J. Oncol. 36, 415–420. doi:10.3892/ijo_00000514
Kimura, J., Tael, M., Shibuya, K., Sasai, Y., Tani, S., Ogawa, Y., et al. (2007). Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-kit in small cell lung cancer cells. Canc. Res. 67, 6304–6311.
Kim, J., Mori, T., Chen, S. L., Amedei, F. F., Martinez, S. R., Kuo, C., et al. (2006). Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann. Surg. 244, 1137–1148. doi:10.1097/01.sla.0000217690.65999.9c
Kim, S. Y., Lee, C. H., Midura, B. V., Yeung, C., Mendoza, A., Hong, S. H., et al. (2008). Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis 25, 201–211. doi:10.1007/s10585-007-9133-3

Kioi, M., Vogel, H., Schultz, G., Hoffman, R. M., Harsh, G. R., Brown, J. M., et al. (2010). Inhibition of vasculosgenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694–705. doi:10.1172/JCI40283

Klein, K. R., Karpinchik, N. O., Espenschied, S. T., Willcockson, H. H., Dunworth, W. P., Hoopes, S. L., et al. (2014). Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development. Dev. Cell 30, 528–540. doi:10.1016/j.devcel.2014.07.012

Komorowski, M. P., McGrory, A. R., Kolakowska, A., Eng, K., Gil, M., Opprchal, M., et al. (2016). Reprogramming antitumor immunity against chemoresistant ovarian cancer by a c4crx4 antagonist-armed viral oncology. Mol Ther Oncolytics 3, 16034. doi:10.1038/mtso.2016.34

Konopleva, M. Y., and Jordan, C. T. (2011). Leukemia stem cells and their inhibitors in angiogenesis. J. Clin. Oncol. 29, 591. doi:10.1200/JCO.2010.31.0904

Krohn, A., Song, Y. H., Muehleb, F., Droll, L., Beckmann, C., and Alt, E. (2009). CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro. Canc. Lett. 280, 65–71. doi:10.1016/j.clet.2009.02.005

Kucia, M., Reza, R., Miekus, K., Wanzec, J., Wajakowski, W., Janowska-Wieczorek, A., et al. (2005). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1/CXCR4 axis. Stem cells 23, 879–894. doi:10.1634/stemcells.2004-0342

Kufareva, I., Salanga, C. L., and Handel, T. M. (2015). Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies. Immunol. Cell Biol. 93, 372–383. doi:10.1007/s11015.2015.15

Kukreja, P., Abdel-Mageed, A. B., Mondal, D., Liu, K., and Agrawal, K. C. (2005). Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1 (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kB activation. Canc. Res. 65, 9891–9898. doi:10.1158/0008-5472.CAN-05-1293

Kwong, J., Kulbe, H., Wong, D., Chakravarty, P., and Balkwill, F. (2009). An association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis. Histopathology 64, 701–712. doi:10.1111/j.1365-2303.2008.012321

Ma, W., Liu, Y., Ellisin, N., and Shen, J. (2013). Induction of C-X-C chemokine receptor type 7 (CXCR7) switches stromal cell-derived factor-1 (SDF-1) signaling and phagocytic activity in macrophages linked to atherosclerosis. J. Biol. Chem. 288, 15481–15494. doi:10.1074/jbc.M112.445510

Madden, S. L., Cook, B. P., Nacht, M., Weber, W. D., Callahan, M. R., Jiang, Y., et al. (2004). Vascular gene expression in nonneoplastic and malignant brain. Am. J. Pathol. 165, 601–608. doi:10.1016/S0002-9440(10)63324-x

Mao, W., Yi, X., Qin, J., Tian, M., and Jin, G. (2016). CXCL12/CXCR4 axis improves migration of neuroblasts along corpus callosum by stimulating MMP-2 secretion after traumatic brain injury in rats. Neurochem. Res. 41, 1315–1322. doi:10.1007/s11064-018-1381-2

Marchesi, F., Monti, P., Leone, B. E., Zerbi, A., Vecchi, A., Piemonti, L., et al. (2004). Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Canc. Res. 64, 8420–8427. doi:10.1158/0008-5472.CAN-04-1343

Martinez-Ordejón, A., Seoane, S., Cabenas, P., Eiro, N., Sendon-Lago, J., Macia, M., et al. (2018). Breast cancer metastasis to liver and lung is facilitated by pit-1/cxcl12/cxcr4 axis. Oncogene 37, 1340–1344. doi:10.1038/s41388-017-0036-8

Matsukasa, S., Cao, S., Hanna, D., Sunakawa, Y., Ueno, M., Mizunuma, N., et al. (2017). CXCR7 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics J. 17, 535–550. doi:10.1038/s41388-016-0101

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W., Chang, F., et al. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773, 1263–1284. doi:10.1016/j.bbamcr.2006.10.001

McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., et al. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin receptor-like receptor. Nature 393, 333–339. doi:10.1038/sj.nature.4101666

Meijer, J., Ogink, J., and Roos, E. (2008). Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br. J. Canc. 99, 1493–1501. doi:10.1093/brnc/6604727

Mellado, M., Rodríguez-Strade, J. M., Vila-Coro, A. J., Fernández, S., Martín de Ana, A., Jones, D. R., et al. (2001). Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 20, 2497–2507. doi:10.1093/emboj/20.10.2497

Miao, Z., Luker, K. E., Summers, B. C., Berzovich, R., Bohjani, M. S., Rehentulla, A., et al. (2007). CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. U.S.A. 104, 15735–15740. doi:10.1073/pnas.061044104

Monnier, J., Boissain, M., L’Helgoualc’h, A., Lacombe, M. L., Turlin, B., Zacmann-Rossi, I., et al. (2012). CXCR7 is up-regulated in human and marine
hepatocellular carcinoma and is specifically expressed by endothelial cells. *Eur. J. Cancer* 48, 138–148. doi:10.1016/j.ejca.2011.06.044

Müller, A., Homye, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. *Nature* 410, 50–56. doi:10.1038/35065016

Naumann, U., Camerini, E., Prenster, M., Mahabaleshwar, H., Raz, E., Zewes, H., et al. (2010). CXCR7 functions as a scavenger for CXCL12 and CXCL11. *PLoS One* 5, e9175. doi:10.1371/journal.pone.0009175

Nomiyama, H., Osada, N., and Yoshie, O. (2013). Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. *Gene Cell.* 18, 1–16. doi:10.1111/gtc.12103

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, F., et al. (2013). SDF-1/CXCR4/CXCR7 axis in cancer. *Future Oncol.* 9, 1381–1397. doi:10.2217/fon.13.096

Pan, F., Ma, S., Cao, W., Liu, H., Chen, F., Chen, X., et al. (2013). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell 121*, 335–348. doi:10.1016/j.cell.2005.02.034

Pan, F., Ma, S., Cao, W., Liu, H., Chen, F., Chen, X., et al. (2013). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell 121*, 335–348. doi:10.1016/j.cell.2005.02.034

Ratajczak, M., Zuba-Surma, E., Kucia, M., Reca, R., Wojakowski, W., and Qin, L. F., Qin, J. M., Zhang, J. Q., Lv, X. P., Huang, L. Y., and Wang, J. J. (2018). *Frontiers in Pharmacology* | www.frontiersin.org December 2020 | Volume 11 | Article 574667

Rubin, J. B. (2009). Chemokine signaling in cancer: one hump or two? *Semin. Canc. Biol.* 19, 116–122. doi:10.1016/j.semcancer.2008.10.001

Saigusa, S., Toiyama, Y., Tanaka, K., Yokoe, T., Okugawa, Y., Kawai, A., et al. (2010). Stromal CXCL4 and CXCR4 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. *Ann. Surg Oncol.* 17, 2051–2059. doi:10.1245/s10434-010-0970-y

Saini, V., Staren, D. M., Ziarek, J. J., Nashaat, Z. N., Campbell, E. M., Volkman, B. F., et al. (2011). The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions. *J. Biol. Chem.* 286, 33466–33477. doi:10.1074/jbc.M111.337342

Shi et al. CXCL12/CXCR4/CXCR7 Axis in Cancer

Singh, R. K., and Lokeshwar, B. L. (2011). The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. *Canc. Res.* 71, 3268–3277. doi:10.1158/0008-5472.CAN-10-2769

Sleighthoml, R. L., Neilson, B. K., Li, J., Steele, M. M., Singh, R. K., Hollingsworth, M. A., et al. (2017). Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. *Pharmacol. Ther.* 179, 158–170. doi:10.1016/j.pharmthera.2017.05.012

Spill, F., Reynolds, D. S., Kamm, R. D., and Zaman, M. H. (2016). Impact of the physical microenvironment on tumor progression and metastasis. *Curr. Opin. Biotechnol.* 40, 41–48. doi:10.1016/j.copbio.2016.02.007

Sreedharan, S. P., Robichon, A., Peterson, K. E., and Goetzl, E. J. (1991). Cloning and expression of the human vasoactive intestinal peptide receptor. *Proc. Natl. Acad. Sci. U.S.A.* 88, 4986–4990. doi:10.1073/pnas.88.11.4986

Shi et al. CXCL12/CXCR4/CXCR7 Axis in Cancer

Singh, A. P., Arora, S., Bhardwaj, A., Srivastava, S. K., Kadakia, M. P., Wang, B., et al. (2012). CXCL4/CXCR4 protein signaling axis is overexpressed in and required for proliferation of glioblastoma tumor cells. *J. Surg. Oncol.* 69, 99–104. doi:10.1002/(sici)1096-9098(199810)69:2<99::aid-suto>3.0.co;2-m

Shaked, Y., Henke, E., Roodhart, J. M., Mancuso, P., Langenbruch, M. H., Colleoni, M., et al. (2008). Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. *Canc. Cell.* 14, 263–273. doi:10.1016/j.ccc.2008.08.001

Shen, X., Wang, S., Wang, H., Liang, M., Xiao, L., and Wang, Z. (2009). The role of SDF-1/CXCR4 axis in ovarian cancer metastasis. *J. Huazhong Univ. Sci. Technol.—Med. Sci.* 39, 363–367. doi:10.1016/j.jhust.2008.09.035

Singh, A. P., Arora, S., Bhardwaj, A., Srivastava, S. K., Kadakia, M. P., Wang, B., et al. (2012). CXCL4/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions. *J. Biol. Chem.* 287, 39115–39124. doi:10.1074/jbc.M112.409581

Singh, R. K., and Lokeshwar, B. L. (2011). The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. *Canc. Res.* 71, 3268–3277. doi:10.1158/0008-5472.CAN-10-2769

Sleighthoml, R. L., Neilson, B. K., Li, J., Steele, M. M., Singh, R. K., Hollingsworth, M. A., et al. (2017). Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. *Pharmacol. Ther.* 179, 158–170. doi:10.1016/j.pharmthera.2017.05.012

Spill, F., Reynolds, D. S., Kamm, R. D., and Zaman, M. H. (2016). Impact of the physical microenvironment on tumor progression and metastasis. *Curr. Opin. Biotechnol.* 40, 41–48. doi:10.1016/j.copbio.2016.02.007

Sreedharan, S. P., Robichon, A., Peterson, K. E., and Goetzl, E. J. (1991). Cloning and expression of the human vasoactive intestinal peptide receptor. *Proc. Natl. Acad. Sci. U.S.A.* 88, 4986–4990. doi:10.1073/pnas.88.11.4986
Stacer, A. C., Fenner, J., Cavnar, S. P., Xiao, A., Zhao, S., Chang, S. L., et al. (2016). Endothelial CXCR7 regulates breast cancer metastasis. Oncogene 35, 1716–1724. doi:10.1038/onc.2015.236

Sun, Y., Cheng, Z., Ma, L., and Pei, G. (2002). Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J. Biol. Chem. 277, 49212–49219. doi:10.1074/jbc.M207294200

Suzuki, Y., Rahman, M., and Mitsuya, H. (2001). Diverse transcriptional response to chemokine receptor stimulation. Trends Immunol. 22, 80–87. doi:10.1016/S1471-4906(01)01789-4

Vicari, A. P., and Caux, C. (2002). Chemokines in cancer. Cancer Metastasis Rev. 21, 391–409. doi:10.1023/A:1020110823133

Ward, S. G. (2006). T lymphocytes on the move: chemokines, PI 3-kinase and priming effects of SDF-1 on CD4+ T cells. J. Biol. Chem. 281, 2513–2519. doi:10.1074/jbc.M508845200

Wang, J. F., Park, I. W., and Groopman, J. E. (2000). Stromal cell-derived factor-1 (SDF-1/CXCR4) signaling up-regulates survivin to regulate human breast cancer cell cycle and epithelial-mesenchymal transition via ERK and PI3K/akt pathway. Med. Oncol. 17, 2757–2764. doi:10.1046/j.1532-7947.2000.00389.x

Yang, D., Xin, M., Wang, J., Xu, H., Huo, Q., Tang, Z., et al. (2015a). Chemokine receptor CXCR4 receptor and its ligand CXCL12 expressions and clinical significance in bladder cancer. J. Cancer Res. Ther. 11, 983–988. doi:10.4103/0973-1482.163085

Yu, T., Wu, Y., Helman, J. I., Wen, Y., Wang, C., and Li, L. (2011). CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol. Cancer Res. 9, 161–172. doi:10.1158/1541-7786.MCR-10-0386

Zabel, B. A., Wang, Y., Lewen, S., Berahovich, R. D., Penfold, M. E., Zhang, P., et al. (2009). Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J. Immunol. 183, 3204–3211. doi:10.4049/jimmunol.0900269

Zagzag, D., Lukyanov, Y., Lan, L., Ali, M. A., Esencay, M., Mendez, O., et al. (2006). Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab. Invest. 86, 1221–1232. doi:10.1038/lab.2006.370482

Zelenberg, I. S., Ruuls- Van Stalle, L., and Roos, E. (2003). The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 63, 3833–3839

Zeng, Z., Shi, Y., Samudio, I. J., Wang, R. Y., Ling, X., Frolova, O., et al. (2009). Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215–6224. doi:10.1182/blood-2008-05-158311

Zhang, S., Qi, L., Li, M., Zhang, D., Xu, S., Wang, N., et al. (2008). Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J. Exp. Clin. Cancer Res. 27, 62. doi:10.1186/1756-9966-27-62

Zhang, Q., Shuai, X., Ye, Y., Jin, Y., Jiang, N., Chen, X., et al. (2016). The role of phosphorylomes of stromal-derived factor-1 and CXCR4 receptor 4 in acute myeloid leukemia and leukemia cell dissemination. Gene 588, 103–108. doi:10.1016/j.gene.2016.04.059

Zhi, Y., Lu, H., Duan, Y., Sun, W., Guan, G., Dong, Q., et al. (2015). Involvement of CXCR7 in breast carcinoma cells. Cytokine Growth Factor Rev. 26, 428–433. doi:10.1016/j.cgr.2014.09.005

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Shi, Riese and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in any form of this work is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Shi et al. CXCL12/CXCR4/CXCR7 Axis in Cancer